Pulsetto: Does It Really Improve Sleep by 41%?

“Sleep improved 41%” is the kind of number that makes a wellness-device claim feel unusually concrete. It is not just “may support sleep” or “helps you relax.” Pulsetto puts a percentage on the outcome and a timeline on the result: four weeks.

That made this claim more interesting than the usual vagus-nerve marketing language. A precise number should have a traceable origin, so I went looking for it. In this case, there really is a study of the exact Pulsetto device behind the headline. But the study design matters just as much as the percentage.

The short version is that the 41% figure is not invented. It appears to reflect an improvement in a sleep questionnaire during a small four-week Pulsetto study. What it does not show is that Pulsetto caused a 41% improvement compared with placebo, or that a typical buyer should expect their sleep to improve by that amount.

What Pulsetto actually claims

On its current website, Pulsetto says: “Stress dropped 56%. Sleep improved 41%. All in just 4 weeks.” The company describes a study in which 40 people used the device twice a day for four weeks. It also presents a progression from 32% improved sleep quality at week two to 41% at week four.

Pulsetto is a neck-worn electrical stimulation device designed to stimulate the vagus nerve without surgery. The broader pitch is that vagus-nerve stimulation can help shift the nervous system toward a calmer state, which in turn may make it easier to relax and sleep.

That general mechanism is scientifically plausible. The more important question for this article is narrower: what does the specific 41% number mean, and how confidently can it be attributed to this device?

Where the 41% number comes from

The strongest direct evidence I found is a 2026 European Psychiatry congress abstract evaluating Pulsetto in healthy adults. Forty people ages 21 to 64 enrolled, and 37 completed the study.

Participants used non-invasive vagus-nerve stimulation over four weeks. The study compared unilateral and bilateral stimulation and measured several outcomes, including depressive symptoms, anxiety, sleep quality, hair cortisol, and hair cortisone. Sleep was assessed with the Pittsburgh Sleep Quality Index, usually shortened to PSQI.

This is an important point in Pulsetto’s favor: the marketing statistic is tied to research on the actual product rather than being borrowed entirely from studies of unrelated vagus-nerve devices.

But the study is not the same thing as a randomized placebo-controlled trial showing that Pulsetto improves sleep by 41%.

The missing control group changes the interpretation

The published abstract describes unilateral and bilateral stimulation groups, but it does not describe an inactive or sham-stimulation control group. Everyone was receiving some form of the intervention.

That makes a before-and-after improvement interesting, but it creates a basic causal problem. If sleep scores improve over four weeks, we do not know how much of that change came from electrical vagus-nerve stimulation itself.

People who enroll in a wellness study may change their routines. They may pay more attention to sleep. Expectations can affect subjective questionnaire scores. Symptoms also fluctuate naturally, and people often enter studies when a problem feels particularly noticeable, creating room for regression toward their usual baseline.

A sham group helps separate those effects from the effect of the active device. Without one, the study can show that sleep scores changed while people were using Pulsetto. It cannot cleanly show how much Pulsetto caused them to change.

That distinction is especially important when marketing turns a questionnaire change into a simple statement such as “Sleep improved 41%.” To a shopper, that can sound like an expected treatment effect. The study does not establish that interpretation.

What exactly was measured?

The PSQI is a validated questionnaire used to assess sleep quality across several components, including perceived sleep quality, sleep latency, duration, efficiency, disturbances, medication use, and daytime dysfunction. It is useful in research, but it is not the same as directly measuring every minute of sleep with laboratory polysomnography.

So “41% better sleep” should not be read as 41% more deep sleep, 41% more total sleep time, or a 41% improvement in every aspect of sleep physiology. It refers to change in a sleep-quality score.

That does not make the result meaningless. Patient-reported sleep quality matters. But translating a questionnaire score into a broad consumer phrase can make the result feel more universal and physically measured than it really is.

There are other limitations worth noticing

The study was small. Forty people enrolled and 37 completed it. The participants were healthy adults, so the result should not automatically be treated as evidence that Pulsetto treats clinical insomnia or another sleep disorder.

The publication is also a congress supplement abstract rather than a full-length clinical trial report. That means many details that would help independently evaluate the work are not available in the same depth as they would be in a complete peer-reviewed paper.

One author lists Pulsetto as an affiliation in the open-access version of the abstract. An industry connection does not invalidate a study, but it increases the importance of transparent methods, appropriate controls, preregistration, and independent replication.

The abstract’s conclusion is positive, describing bilateral non-invasive vagus-nerve stimulation as effective for reducing biological stress markers and improving sleep-related and psychological symptoms in healthy adults. The data are useful preliminary evidence. The design simply does not support the strongest causal reading of the marketing percentage.

Does vagus-nerve stimulation help sleep more generally?

This is where the story gets more interesting, because Pulsetto is not relying on a biologically implausible idea.

A 2025 systematic review and meta-analysis examined six studies involving 336 people with insomnia. The pooled results favored transcutaneous auricular vagus-nerve stimulation for both sleep quality and insomnia severity. The average PSQI improvement was statistically significant.

However, the authors rated the certainty of evidence as low for sleep quality and very low for insomnia severity. Six studies are not a huge evidence base, and differences in stimulation protocols and study quality make the exact size of the effect uncertain.

A newer 2026 systematic review and meta-analysis included 14 randomized controlled trials of transcutaneous auricular vagus-nerve stimulation for sleep disorders. Eleven studies entered the meta-analysis, and the pooled results again favored active stimulation for sleep quality and time to fall asleep. The authors nevertheless described the findings as preliminary because of heterogeneity and the limited clinical interpretability of the pooled effect sizes.

So there is a growing research signal here. Non-invasive vagus-nerve stimulation may influence sleep. That makes Pulsetto’s claim more credible than a claim built on mechanism alone.

But Pulsetto is not the same intervention used in most sleep trials

There is another important bridge the evidence has to cross. Much of the randomized sleep literature uses transcutaneous auricular vagus-nerve stimulation, meaning stimulation is applied at parts of the ear associated with vagal innervation.

Pulsetto is worn on the neck and targets the cervical region. Both approaches fall under the broad umbrella of non-invasive vagus-nerve stimulation, but they are not interchangeable devices.

Electrical stimulation depends on location, waveform, frequency, pulse width, intensity, session length, electrode contact, and treatment schedule. Evidence that one protocol affects sleep cannot automatically tell us the effect size of another protocol.

This is why the Pulsetto-specific study matters. It begins to build the missing bridge between general vagus-nerve research and the exact consumer device. It just does not finish that bridge yet because the study lacks a sham comparator and remains small and preliminary.

What would make the 41% claim much stronger?

The clearest next step would be a preregistered randomized trial comparing Pulsetto with a convincing sham device. Participants and outcome assessors should be blinded where practical, and the protocol should specify the primary sleep outcome before results are known.

A larger sample would help, as would a population matched to the intended claim. If the goal is general sleep support in healthy adults, study that population. If the marketing moves toward insomnia treatment, then people with clinically characterized insomnia would need to be studied separately.

It would also be useful to combine questionnaires such as PSQI with objective sleep measures. Wearables can provide additional real-world information, while polysomnography can answer more detailed physiological questions in a smaller laboratory sample.

Most importantly, the marketing statistic should be expressed in the same terms as the study. “A 41% change in a sleep-quality questionnaire in a four-week uncontrolled study” communicates something quite different from “sleep improved 41%.”

What this means for consumers

Pulsetto now has more product-specific evidence than many wellness gadgets that simply point to research on an ingredient or technology category. That deserves recognition. The exact device has been studied in humans, and the reported sleep result is directionally consistent with a broader body of vagus-nerve stimulation research.

At the same time, the headline percentage is more confident than the study design allows. There was no inactive comparison group in the published four-week study, the sample was small, the participants were healthy adults, and the evidence is currently available as a short congress abstract.

A buyer should therefore read 41% as an observed change in that particular study—not as a guaranteed improvement, not as a placebo-adjusted effect, and not as proof that Pulsetto treats insomnia.

The most interesting conclusion is somewhere in the middle. There is enough evidence here to take the technology seriously, but not enough to treat the marketing percentage as a settled estimate of what the device itself will do.

Claim Verdict: Technically True, But Misleading

Technically True, But Misleading. Pulsetto’s “sleep improved 41%” figure appears to have a real product-specific research basis. A four-week study of the device reported improvement in PSQI sleep scores, and broader meta-analyses suggest that transcutaneous vagus-nerve stimulation may improve sleep outcomes.

But the headline strips away the limitations that determine what the number means. The Pulsetto study had no inactive or sham comparator, included only 40 enrolled healthy adults, and is currently reported as a congress supplement abstract. Most stronger randomized sleep evidence also involves auricular rather than cervical stimulation.

The 41% number is therefore defensible as a description of an observed within-study change. It becomes misleading when presented in a way that implies a controlled causal effect or a result consumers can generally expect from using Pulsetto.